The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Wesper, a leader in advanced home sleep apnea testing (HSAT), is transforming how obesity and sleep apnea are managed by ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Greater weight loss was linked to lower discontinuation rates, with a 1% reduction in weight lowering the hazard of ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...